Literature DB >> 35015151

The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I-III colorectal cancer patients undergoing surgery.

Shun Sato1, Takayuki Shimizu2, Mitsuru Ishizuka1, Kotaro Suda1, Norisuke Shibuya1, Hiroyuki Hachiya1, Yukihiro Iso1, Kazutoshi Takagi1, Taku Aoki1, Keiichi Kubota1.   

Abstract

PURPOSE: The pan-immune-inflammation value (PIV) is useful for stratifying outcomes in patients with metastatic colorectal cancer. However, it is unclear whether preoperative PIV can predict the surgical outcomes of patients with stage I-III colorectal cancer who receive surgery.
METHODS: The records of 758 patients with stage I-III colorectal cancer who received surgical treatment were retrospectively reviewed. The preoperative PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. The cut-off value was determined using a receiver operating characteristic curve for overall survival.
RESULTS: The cut-off value of the preoperative PIV was 376. Five hundred sixty-eight patients (74.9%) had low values (≤ 376), and 190 (25.1%) had high values (> 376). Univariate and multivariate analyses revealed that the PIV (> 376/ ≤ 376) (HR 2.485; 95% CI 1.552-3.981, P < 0.001) was significantly associated with overall survival, as well as age (> 60/ ≤ 60, years) (HR 1.988; 95% CI 1.038-3.807, P = 0.038), globulin-to-albumin ratio (> 0.83/ ≤ 0.83) (HR 2.013; 95% CI 1.231-3.290, P = 0.005) and postoperative complication (C-D grade III-V/0-II) (HR 1.991; 95% CI 1.154-3.438, P = 0.013). The Kaplan-Meier method and log-rank test showed significant differences in overall survival between patients with stage I-III disease with high (> 376) and low (≤ 376) PIVs.
CONCLUSION: The preoperative PIV is useful for predicting surgical outcomes in patients with stage I-III colorectal cancer.
© 2022. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.

Entities:  

Keywords:  Colorectal cancer; Pan-immune-inflammation value; Surgery

Mesh:

Year:  2022        PMID: 35015151     DOI: 10.1007/s00595-021-02448-6

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.540


  3 in total

Review 1.  The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis.

Authors:  Deniz Can Guven; Taha Koray Sahin; Enes Erul; Saadettin Kilickap; Thilo Gambichler; Sercan Aksoy
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

2.  Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer.

Authors:  Fei Lin; Li-Ping Zhang; Shuang-Yan Xie; Han-Ying Huang; Xiao-Yu Chen; Tong-Chao Jiang; Ling Guo; Huan-Xin Lin
Journal:  Front Oncol       Date:  2022-04-13       Impact factor: 5.738

3.  Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas.

Authors:  Erkan Topkan; Ugur Selek; Ahmet Kucuk; Berrin Pehlivan
Journal:  J Inflamm Res       Date:  2022-09-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.